Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512520 | 0.85 | PDE8B (0.42) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL2120886 | 0.83 | PDE8B (0.41) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL7787688 | 0.83 | KCNK3 (0.44) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL12225863 | 0.82 | PDE8B (0.43) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL86245 | 0.81 | PDE8B (0.42) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL2124328 | 0.80 | METTL3 (0.49) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL2122738 | 0.79 | PDE8B (0.41) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL2517432 | 0.76 | PDE8B (0.41) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL2124396 | 0.76 | PDE8B (0.41) | PDE8BCHEK2METTL3KDM1APRMT5 | |
| SCHEMBL7856604 | 0.75 | KDM1A (0.40) | PDE8BCHEK2METTL3KDM1APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129384-B2 | Imidazo[1,2-a]pyrazines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20110288098-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2011-11-24 | — | — | US | disclosed |
| US-20100160345-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288098-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | PDE8B 328/4885CHEK2 3412/4885METTL3 3733/4885 |
| US-20100160345-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | PDE8B 328/4885CHEK2 3412/4885METTL3 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.